The results demonstrated that, across all datasets, higher GADD45G expression was significantly correlated with improved overall survival (OS) in both glioma and glioblastoma, suggesting that GADD45G may serve as a favorable prognostic biomarker for glioma patients (Figures 2F–K). The gene discussed is GADD45G; the disease is central nervous system cancer.